Receptos radiant on top-line data for Gilenya rival
This article was originally published in Scrip
Receptos jumped 32% in after-hours trading on 9 June after the San Diego-based company said its sphingosine-1-phosphate receptor 1 (S1P1) agonist RPC1063 met the primary endpoint of reduction in MRI brain lesion activity for multiple sclerosis patients enrolled in the Phase II portion of the Phase II/III RADIANCE clinical trial.
You may also be interested in...
Safety Is Key As Celgene's Ozanimod Succeeds In First Pivotal MS Test
Celgene's ozanimod successfully cleared its first Phase III hurdle in multiple sclerosis, but safety will be the S1P receptor modulator's differentiating factor in results presented later this year, with additional value coming from ulcerative colitis and Crohn's disease in the coming years.
Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
Building On Successes During Turbulent Times, SR One Closes $600m Fund II
SR One will keep investing in a mix of new companies, early-stage firms and later opportunities with its second fund, raised even as biotech continues to endure challenging financial times.